UK Medicines and Healthcare Products Regulatory Agency Confirms Acceptance of Marketing Authorization Application for Proposed Biosimilar to Xolair® (omalizumab)
Portfolio Pulse from
Alvotech, in partnership with Kashiv Biosciences and Advanz Pharma, has received marketing authorization application acceptance from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for AVT23, a proposed biosimilar to Xolair. This represents a significant step towards increasing patient access to a biologic treatment for severe persistent allergic asthma and chronic rhinosinusitis with nasal polyps. Global sales of Xolair were approximately $4.4 billion in 2024.
March 26, 2025 | 8:45 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
MHRA's acceptance of AVT23's marketing application represents a key milestone for Alvotech, potentially expanding the company's market presence in biosimilar medicines.
The MHRA application acceptance is a critical step in Alvotech's product development, signaling potential future revenue and market expansion in the biosimilars sector.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100